[
  "http://www.fda.gov/about-fda/fda-commissioner/fh-investments-inc-dba-asteria-health-birmingham-al-483-issued-12192025",
  "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/ipca-laboratories-limited-1252025",
  "http://www.fda.gov/about-fda/fda-commissioner/us-specialty-formulations-llc-allentown-pa-483-issued-1142026",
  "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/baxter-oncology-gmbh-09262025",
  "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/innostar-bio-tech-nantong-company-ltd-1112024",
  "http://www.fda.gov/about-fda/fda-commissioner/empower-clinic-services-llc-dba-empower-pharma-houston-tx-483-issued-12142025",
  "http://www.fda.gov/about-fda/fda-commissioner/denver-solutions-llc-englewood-co-483-issued-12112025",
  "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/joinn-laboratories-co-ltd-09202013",
  "http://www.fda.gov/about-fda/fda-commissioner/nubratori-inc-torrance-ca-483-issued-12112025",
  "http://www.fda.gov/about-fda/fda-commissioner/pine-pharmaceuticals-llc-tonawanda-ny-483-issued-11142025",
  "http://www.fda.gov/about-fda/fda-commissioner/petscript-inc-paris-tx-483-issued-09182025",
  "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/asahi-kasei-finechem-co-ltd-11142025",
  "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/sato-pharmaceutical-co-ltd-11212025",
  "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/lupin-limited-09162025",
  "http://www.fda.gov/about-fda/fda-commissioner/jkr-pharmacy-ventures-llc-dba-doc-lanes-veterinary-pharmacy-lexington-ky-483-issued-12192025",
  "http://www.fda.gov/about-fda/fda-commissioner/fresenius-kabi-compounding-llc-canton-ma-483-issued-11052025",
  "http://www.fda.gov/about-fda/mcneil-healthcare-llc-las-piedras-pr-483-issued-11022010",
  "http://www.fda.gov/drugs/cder-foia-electronic-reading-room/inotiv-inc-10242025",
  "http://www.fda.gov/about-fda/fda-commissioner/osrx-inc-missoula-mt-483-issued-11142025",
  "http://www.fda.gov/about-fda/fda-commissioner/qualgen-llc-edmond-ok-483-issued-09042025",
  "https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-good-manufacturing-practice-medicinal-products-annex-15-qualification-validation_en.pdf",
  "https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-use-bayesian-methods-clinical-development_en.pdf",
  "https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-clinical-evaluation-diagnostic-agents-its-appendix-1-imaging-agents_en.pdf",
  "https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-using-owner-assessment-efficacy-parameter_en.pdf",
  "https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees-revision-2_en.pdf",
  "https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-efficacy-ectoparasiticides-general-requirements_en.pdf",
  "https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-combined-vaccines-associations-immunological-veterinary-medicinal-products-ivmps-revision-1_en.pdf",
  "https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-investigation-assessment-cardiovascular-safety-anticancer-medicinal-products_en.pdf"
]